Comparison of peripherally acting substance for treatment of detrusor overactivity: What is new; what is in the pipeline?

EAU Update Series

Volumn 2, Issue 4 SPEC.ISS., 2004, Pages 161-169

  Tubaro, Andrea ^a   De Nunzio, Cosimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bladder; Drug therapy; Overactive bladder syndrome; Urge incontinence

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM ANTAGONIST; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIZOLIRTINE; DARIFENACIN; ERYTHROMYCIN; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; INDOMETACIN; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; N (4 BENZOYLPHENYL) 3,3,3 TRIFLUORO 2 HYDROXY 2 METHYLPROPIONAMIDE; NIFEDIPINE; OXYBUTYNIN; PINACIDIL; POTASSIUM CHANNEL STIMULATING AGENT; PROPIVERINE; PROSTAGLANDIN INHIBITOR; SOLIFENACIN; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR ANTAGONIST; TAMSULOSIN; TOLTERODINE; UNINDEXED DRUG; VANILLOID RECEPTOR;

ARTICLE; BURNING SENSATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DETRUSOR DYSSYNERGIA; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRY EYE; DYSPEPSIA; EUROPE; HEADACHE; HUMAN; MEDLINE; MEMORY DISORDER; META ANALYSIS; MICTURITION; NAUSEA; NONHUMAN; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PREVALENCE; SOMNOLENCE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TACHYCARDIA; TREMOR; UNITED STATES; URINE INCONTINENCE; URINE RETENTION; VISUAL IMPAIRMENT; VOMITING; XEROSTOMIA;

EID: 10244259316     PISSN: 15709124     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euus.2004.09.001     Document Type: Article

References (42)

1. P. Abrams Describing bladder storage function: Overactive bladder syndrome and detrusor overactivity Urology 62 5 Suppl 2 2003 28-37
2. I. Milsom P. Abrams L. Cardozo R.G. Roberts J. Thuroff A.J. Wein How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU Int 87 9 2001 760-766
3. W.F. Stewart J.B. Van Rooyen G.W. Cundiff P. Abrams A.R. Herzog R. Corey Prevalence and burden of overactive bladder in the United States World J Urol 20 6 2003 327-336
4. T.W. Hu T.H. Wagner J.D. Bentkover K. Leblanc S.Z. Zhou T. Hunt Costs of urinary Incontinence and overactive bladder in the United States: A comparative study Urology 63 3 2004 461-465
5. J.S. Brown W.F. McGhan S. Chokroverty Comorbidities associated with overactive bladder Am J Manag Care 6 11 Suppl 2000 S574-S579
6. W.C. de Groat A neurologic basis for the overactive bladder Urology 50 6A Suppl 1997 36-52
7. A.F. Brading A myogenic basis for the overactive bladder Urology 50 6A Suppl 1997 57-67
8. Abrams P, Anderson KE, Artibani W, Brubaker L, et al. Evaluation an treatment of urinary incontinence, pelvic prolapse and fecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. 2nd Consultation on Incontinence, Paris 2001. Plymouth: Plymbridge Distributors Ltd.; 2002. p. 1079-117.
9. P.S. Goode Behavioral and drug therapy for urinary incontinence Urology 63 3 Suppl 1 2004 58-64
10. J. Hay-Smith P. Herbison G. Ellis K. Moore Anticholinergic drugs versus placebo for overactive bladder syndrome in adults Cochrane Database Syst Rev 3 2002
11. C.R. Chapple T. Yamanishi R. Chess-Williams Muscarinic receptor subtypes and management of the overactive bladder Urology 60 5 Suppl 1 2002 82-88
12. J. Malone-Lee D.J. Henshaw K. Cummings Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response BJU Int 92 4 2003 415-417
13. Andersson K. Pharmacological treatment of urinary incontinence. Abrams P, Cardozo L, Khoury S, Wein A, editors. 2nd Consultation on Incontinence, Paris 2001. Plymouth: Plymbridge Distributors Ltd.; 2002. p. 479-511.
14. J.Y. Gillenwater M. Gray Evidence: What is it, where do we find it, and how do we use it? Eur Urol. Suppl 2 5 2003 3-9
15. C.R. Chapple T. Rechberger S. Al-Shukri P. Meffan K. Everaert M. Huang A. Ridder YM-905 Study Group Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder BJU Int 93 3 2004 303-310
16. Sachse R, Cawello W, Hammes W, Horstmann. Safety and Pharmacokinetics of the novel antimuscarinic drug fesoterodine in populations of different age or gender. Proceedings of the 32nd International Continence Society, Heidelberg. 2002, p. 440
17. R.R. Dmochowski (S)-oxybutynin (Sepracor) Curr Opin Investig Drugs 3 10 2002 1508-1511
18. http://www.sepracor.com.
19. P.E. Van Kerrebroeck G. Amarenco J.W. Thuroff H.G. Madersbacher M.T. Lock E.J. Messelink Dose-ranging study of tolterodine in patients with detrusor hyperreflexia Neurourol Urodyn 17 5 1998 499-512
20. K.E. Anderson Physiological society symposium: The physiology and pathophysiology of the lower urinary tract. Advances in the pharmacological control of the bladder Exp Physiol 84 1999 195-213
21. S. Perlberg M. Caine Adrenergic response of bladder muscle in prostatic obstruction Urology 20 1982 524-527
22. K. Reuter J. Aagoard Alpha adrenergic blockade in the diagnosis of detrusor instability secondary to intravescical obstruction Urol Int 39 1984 312-313
23. P. Abrams G. Amarenco A. Bakke A. Buczynski D. Castro-Diaz S. Harrison G. Kramer R. Marsik A. Prajsner M. Stohrer P. Van Kerrebroeck J.J. Wyndaele European Tamsulosin Neurogenic Lower Urinary Tract Dysfunction Study Group Tamsulosin: Efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury J Urol 170 4 Pt 1 2003 1242-1251
24. Carbone A, Palleschi G, Parascani R, Morello P, Tubaro A, Cristini C. urodynamic evaluation of tamsulosin effect on neurogenic detrusor overactivity. Proceedings 32nd Annual Meeting International Continence Society, Heidelberg, 2002, p. 340-1.
25. O. Yamaguchi Beta3-adrenoceptors in human detrusor muscle Urology 59 5 Suppl 1 2002 25-29
26. International Nonproprietary Names for Pharmaceutical Substances (INN) WHO Drug Information 18 1 2004 41-82
27. http://www.yamanouchi.com.
28. M.A. Zar M.M. Iravani G.N. Luheshi Effect of nifedipine on the contractile responses of the isolated rat bladder J Urol 143 4 1990 835-839
29. R.C. England R.I. Norman R.A. Elliott Direct inhibition of rat detrusor muscle contraction by erythromycin Neurourol Urodyn 23 3 2004 273-279
30. G. Edwards M. Henshaw M. Miller A.H. Weston Comparison of the effects of several potassium-channel openers on rat bladder and rat portal vein in vitro Br J Pharmacol 102 3 1991 679-680
31. J.H. Li G.D. Yasay P. Zografos S.T. Kau C.J. Ohnmacht K. Russell Zeneca ZD6169 and its analogs from a novel series of anilide tertiary carbinols: In vitro KATP channel opening activity in bladder detrusor Pharmacology 51 1 1995 33-42
32. A.M. Abdel-Karim R.A. Bialecki M.M. Elhilali Effects of ZD6169 and ZD0947, 2 potassium adenosine triphosphate channel openers, on bladder function of spinalized rats J Urol 168 2 2002 837-842
33. M. Gopalakrishnan S.A. Buckner K.L. Whiteaker C.C. Shieh E.J. Molinari I. Milicic
34. M.E. Brune T.A. Fey J.D. Brioni J.P. Sullivan M. Williams W.A. Carroll
35. M. Tanaka Y. Sasaki Y. Kimura T. Fukui K. Hamada Y. Ukai A novel pyrrole derivative, NS-8, suppresses the rat micturition reflex by inhibiting afferent pelvic nerve activity BJU Int 92 9 2003 1031-1036
36. L.D. Cardozo S.L. Stnaton H. Robinson Evaluation of flurbiprofen in detrusor instability Br Med J 280 1980 281-282
37. L.D. Cardozo S.L. Stanton A comparison between bromocriptine and indomethacin in the treatment of detrusor instability J Urol 123 1980 399-401
38. http://www.nicox.com.
39. A. Choppin G. Groke A. Bringas G. Stepan M.P. Dillon Effect of YM-44781, YM-44778 and YM-49598, novel tachykinin antagonists, in a drug-induced bladder contraction model Pharmacology 65 2 2002 96-102
40. http://www.pharma-transfer.com.
41. M. Lazzeri P. Beneforti D. Turini Urodynamic effects of intravesical resiniferatoxin in humans: Preliminary results in stable and unstable detrusor J Urol 158 6 1997 2093-2096
42. http://www.icos.com.